×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ONVO – organovo holdings, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ONVO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
08:11 am
onvo
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting [Yahoo! Finance]
Low
Report
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting [Yahoo! Finance]
11/20
08:05 am
onvo
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
Medium
Report
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
11/19
03:02 am
onvo
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
High
Report
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/14
01:02 pm
onvo
Global Organoids Market to Surge Significantly at a CAGR of ~14% by 2030 | DelveInsight [Yahoo! Finance]
Low
Report
Global Organoids Market to Surge Significantly at a CAGR of ~14% by 2030 | DelveInsight [Yahoo! Finance]
11/13
08:13 am
onvo
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases [Yahoo! Finance]
Low
Report
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases [Yahoo! Finance]
11/13
08:06 am
onvo
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
Medium
Report
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
11/11
02:05 am
onvo
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
11/3
02:07 am
onvo
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
03:35 pm
onvo
Form SC 13G ORGANOVO HOLDINGS, INC. Filed by: ARMISTICE CAPITAL, LLC
Medium
Report
Form SC 13G ORGANOVO HOLDINGS, INC. Filed by: ARMISTICE CAPITAL, LLC
11/8
04:05 pm
onvo
Form 10-Q ORGANOVO HOLDINGS, INC. For: Sep 30
Low
Report
Form 10-Q ORGANOVO HOLDINGS, INC. For: Sep 30
10/25
05:01 pm
onvo
Form S-1 ORGANOVO HOLDINGS, INC.
Low
Report
Form S-1 ORGANOVO HOLDINGS, INC.
10/7
04:06 pm
onvo
Form DEFA14A ORGANOVO HOLDINGS, INC.
Low
Report
Form DEFA14A ORGANOVO HOLDINGS, INC.
10/7
04:06 pm
onvo
Form ARS ORGANOVO HOLDINGS, INC. For: Mar 31
Low
Report
Form ARS ORGANOVO HOLDINGS, INC. For: Mar 31
10/7
04:05 pm
onvo
Form DEF 14A ORGANOVO HOLDINGS, INC. For: Oct 04
Low
Report
Form DEF 14A ORGANOVO HOLDINGS, INC. For: Oct 04
9/18
04:06 pm
onvo
Form PRE 14A ORGANOVO HOLDINGS, INC. For: Sep 18
Low
Report
Form PRE 14A ORGANOVO HOLDINGS, INC. For: Sep 18
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/30
Organovo Collaborates With MCRI and Leiden University Medical Center to Develop Stem Cell-Based Bioprinted Tissue Treatments for Kidney Disease
96.5%
3/31 Form SEC STAFF LETTER ORGANOVO HOLDINGS, INC. 34.4%
12/16 Organovo and Tarveda Therapeutics Announce Definitive Merger Agreement 20.6%
11/14 Organovo Holdings Inc (NASDAQ: ONVO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 18.8%
6/28 Form 8-K ORGANOVO HOLDINGS, INC. For: Jun 25 13.9%
4/7 Organovo Announces Termination of Merger Agreement with Tarveda Therapeutics 13.6%
7/10 Form SC 13G/A ORGANOVO HOLDINGS, INC. Filed by: BlackRock Inc. 12.5%
10/2 Organovo Acknowledges Receipt of Proposal 5.6%
10/2 Viscient Biosciences Proposes Merger to Unlock 3D Bioprinting Potential in Drug Discovery With Organovo 3.7%
10/11 Form 8-K ORGANOVO HOLDINGS, INC. For: Oct 10 3.7%
3/31 Form SEC STAFF LETTER ORGANOVO HOLDINGS, INC. 34.4%
12/16 Organovo and Tarveda Therapeutics Announce Definitive Merger Agreement 20.6%
11/14 Organovo Holdings Inc (NASDAQ: ONVO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 18.8%
6/28 Form 8-K ORGANOVO HOLDINGS, INC. For: Jun 25 13.9%
4/7 Organovo Announces Termination of Merger Agreement with Tarveda Therapeutics 13.6%
7/10 Form SC 13G/A ORGANOVO HOLDINGS, INC. Filed by: BlackRock Inc. 12.5%
10/2 Organovo Acknowledges Receipt of Proposal 5.6%
10/2 Viscient Biosciences Proposes Merger to Unlock 3D Bioprinting Potential in Drug Discovery With Organovo 3.7%
10/11 Form 8-K ORGANOVO HOLDINGS, INC. For: Oct 10 3.7%
TOP News Decliners
5/22
Organovo Updates Key Clinical Development Goals; Company Reports Preliminary Fiscal Fourth-Quarter 2019 Results
-39.5%
8/7 Organovo to Explore Strategic Alternatives and Implement Restructuring Plan -35.8%
3/31 Organovo Holdings, Inc. Reminds Stockholders About Adjourned Special Meeting of Stockholders -23.7%
5/23 Organovo Holdings, Inc. (ONVO) CEO Taylor Crouch on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -17.0%
4/2 Organovo Holdings Founder Calls on Board of Directors to Accept Stockholders’ Opposition to the Illogical Merger With Tarveda Therapeutics -15.5%
12/30 Form 425 ORGANOVO HOLDINGS, INC. Filed by: ORGANOVO HOLDINGS, INC. -14.0%
1/21 Form PX14A6G ORGANOVO HOLDINGS, INC. Filed by: Murphy Keith -13.1%
3/20 Form 425 ORGANOVO HOLDINGS, INC. Filed by: ORGANOVO HOLDINGS, INC. -10.8%
3/13 Form CT ORDER ORGANOVO HOLDINGS, INC. -10.1%
2/24 Form 424B3 ORGANOVO HOLDINGS, INC. -9.3%
8/7 Organovo to Explore Strategic Alternatives and Implement Restructuring Plan -35.8%
3/31 Organovo Holdings, Inc. Reminds Stockholders About Adjourned Special Meeting of Stockholders -23.7%
5/23 Organovo Holdings, Inc. (ONVO) CEO Taylor Crouch on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -17.0%
4/2 Organovo Holdings Founder Calls on Board of Directors to Accept Stockholders’ Opposition to the Illogical Merger With Tarveda Therapeutics -15.5%
12/30 Form 425 ORGANOVO HOLDINGS, INC. Filed by: ORGANOVO HOLDINGS, INC. -14.0%
1/21 Form PX14A6G ORGANOVO HOLDINGS, INC. Filed by: Murphy Keith -13.1%
3/20 Form 425 ORGANOVO HOLDINGS, INC. Filed by: ORGANOVO HOLDINGS, INC. -10.8%
3/13 Form CT ORDER ORGANOVO HOLDINGS, INC. -10.1%
2/24 Form 424B3 ORGANOVO HOLDINGS, INC. -9.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: